|
Sign In to gain access to subscriptions and/or personal tools.
|
Proliferative Lesions of Ovarian Granulosa Cells and Reversible Hormonal Changes Induced in Rats by a Selective Estrogen Receptor Modulator
Gerald G. Long
Toxicology and Drug Disposition, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfi eld, IN, 46140, Long_Gerald_G{at}Lilly.com.
Ilene R. Cohen
Toxicology and Drug Disposition, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfi eld, IN, 46140
Christian L. Gries
Toxicology and Drug Disposition, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfi eld, IN, 46140
Jamie K. Young
Toxicology and Drug Disposition, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfi eld, IN, 46140
Paul C. Francis
Toxicology and Drug Disposition, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfi eld, IN, 46140
Charles C. Capen
Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, 43210
This study assessed the effects of raloxifene, a selective estrogen receptor modulator (SERM), on ovarian morphology and circulating hormone levels in rats. Female Fischer-344 rats (65/group) were given dietary raloxifene for 6 months at average daily doses of 0, 15, 75, and 365 mg/kg. Morphologic evaluation of ovaries was conducted on 25 rats/group at the end of the treatment period and from 20 rats per group after 1 and 3 months withdrawal from treatment. Plasma hormone analyses were conducted on 10 rats per group at the end of the treatment period and after each withdrawal period.
Treatment with raloxifene for 6 months resulted in disruption of the hypothalamic-pituitary-ovaria n axis, manifested by increased plasma concentrations of luteinizing hormone (LH) and estradiol-17β (E2), and failure of ovulation, manifested by ovarian follicular prominence (retained anovulatory follicles), lack of corpora lutea (CL), and depressed plasma progesterone (P4). Many (56% to 80%) rats in all raloxifene treated groups had focal, minimal to slight hyperplasia of granulosa cells within individual retained follicles. A few treated rats in the mid- and high-dose groups (2 of 25 and 3 of 25, respectively) had more extensive focal proliferation of granulosa cells. These foci were approximately 3 to 6 mm in overall size and were characterized by moderate papillary proliferation of large granulosa cells associated with cystic spaces, often with hemorrhage. In 4 of the 5 rats with this focal cystic granulosa cell hyperplasia, the remainder of the involved ovary and the contralateral ovary were atrophic.
After 1 or 3 months of drug withdrawal, most previously treated rats examined had morphologic evidence of ovarian cyclic changes, including developing follicles, various stages of CL, and normal plasma levels of LH, E2, and P4. Continued lack of cyclic changes was limited to 4 of 20 rats from the low-dose group after 1 month of recovery and to 1 low dose rat after 3 months. Intrafollicular granulos a cell hyperplasi a was not seen in rats in the reversibility phase. Areas of prior focal cystic granulosa cell hyperplasia were represented by focal sclerosis that included hemorrhage and/or hemosiderin. The foci of sclerosis were associated with cystic spaces after 1 month and were solid after 3 months.
A granulosa cell tumor, approximately 12—13 mm diameter, was present in a high-dose rat in the 3-month reversibility group. This tumor effaced 1 ovary and was characterized by proliferative granulosa cells, usually in papillary formations and cords within cystic spaces. This rat had atrophy of the uninvolved ovary, excessive plasma levels of E2 and prolactin, and high P4 levels considering the absence of CL.
The results of this study indicate that ovarian granulos a cells in rats are susceptibl e to proliferative changes when stimulated chronicall y with excessive trophic hormones. Most of these proliferative changes were reversible upon cessation of the hormonal stimulation. However, the proliferative lesion in one treated rat progressed to apparent autonomous (neoplastic) growth.
Key Words: Estrogen receptor • granulosa cells • granulosa cell tumor • selective estrogen receptor modulator.
References
- Alison RH, Capen CC, Prentice DE (1994). Neoplastic lesions of questionable signifi cance to humans. Toxicol Pathol 22: 179—186.[Abstract/Free Full Text]
- Biskind MS, Biskind GS (1944). Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 55: 176—179.[CrossRef]
- Blaakaer J., Djursing H., Hording U., Bennett P., Toftager-Larsen K., Bock JE, Lebech PE (1992). The pituitary-gonada l axis in women with benign or malignant ovarian tumors. Acta Endocrinol (Copenh) 127: 127—130.[Abstract/Free Full Text]
- Brambell FWR, Parkes AS, Fielding U. (1937). Changes in the ovary of the mouse following exposure to X-rays. Proc Roy Soc London Series B 101: 29—60.
- Capen CC, Beamer WG, Tennent BJ, Stitzel KA (1995). Mechanisms of hormone-mediated carcinogenesis of the ovary in mice. Mutat Res 333: 143—151.[Web of Science][Medline]
[Order article via Infotrieve]
- Capen CC (1996). Hormonal imbalances an mechanisms of chemical injury of the thyroid gland. In: Monographs on Pathology of Laboratory Animals Endocrine System, Jones TC, Capen CC, Mohr U (eds). Berlin, Springer, pp 217—238.
- Cohen IR, Sims ML, Robbins MR, Laksmanan MC, Francis PC, Long GG ( 2000). The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice. Repro Toxicol 14: 37—44.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cramer DW, Barbieri RL, Muto MG, Kelly A., Brucks JP, Harlow BL (1994). Characteristics of women with a family history of ovarian cancer. II. Follicular phase hormone levels. Cancer 74: 1318—1322.[Medline]
[Order article via Infotrieve]
- Davis BJ, Maronpot RR (1996). Chemically associated toxicity and carcinogenicity of the ovary. Prog Clin Biol Res 394: 285—308.[Medline]
[Order article via Infotrieve]
- Dixon D., Leininger JR, Valerio MG, Johnson AN, Stabinski LG, Frith CH (1999). Proliferative lesions of the ovary, uterus, vagina, cervix and oviduct in rats. In: Guides for Toxicologic Pathology, STP/ARP/AFIP, Washington, DC, pp 2—5.
- Dunnett CW (1964). New tables for multiple comparisons with a control. Biometrics 20: 482—491.[Medline]
[Order article via Infotrieve]
- Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. (1985). Toxicological studies on omeprazole. Scand J Gastroenterol 20 (Suppl 108): 53—69.[CrossRef]
- Eli Lilly and Company (1997 ). Evista® Package Insert. Indianapolis, IN.
- Ettinger B., Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T., Genant HK, Christiansen C., Delmas PD, Zanchetta JR, Stakkestad J., Gluer CC, Krueger K., Cohen FJ, Eckert S., Ensrud KE, Avioli LV, Lips P., Cummings SR (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosi s treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282: 637—645.[Abstract/Free Full Text]
- Fisher B., Costantino JP, Wickerham DL, Redmond CK, Kavanah M., Cronin WM, Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371—1388.[Abstract/Free Full Text]
- Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. (1996). Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HC1, tamoxifen, estrogen, and alendronate. Bone 18: 621—627.[Medline]
[Order article via Infotrieve]
- Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C., Bush TL, Hoffman SC, Comstock GW (1995). Serum gonadotropin s and steroid hormones and the development of ovarian cancer. JAMA 274: 1926—1930.[Abstract/Free Full Text]
- Hoyt JA, Fisher LF, Buelke-Sam JL, Francis PC (1998). The selective estrogen receptor modulator, raloxifene: Reproductive assessments following premating exposure in female rats. Repro Toxicol 12: 233—245.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Korach KS (1994). Insights from the study of animals lacking functional estrogen receptor. Science 266: 1524—1527.[Abstract/Free Full Text]
- Levene H. (1960). Robust tests for equality of variances. In: Contributions to Probability and Statistics, Olkin I, Ghurye SG, Hoeffding W, Madow WG, Mann HB (eds). Stanford University Press, Stanford, CA, pp 278— 292.
- Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. (1993). Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA. 90: 11162—11166.[Abstract/Free Full Text]
- McClain RM (1989). The signifi cance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol Pathol 17: 294—306.[Web of Science][Medline]
[Order article via Infotrieve]
- Marchant J. (1957). The chemical induction of ovarian tumours in mice. Br J Cancer 11: 452—464.[Web of Science][Medline]
[Order article via Infotrieve]
- Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. (1992). Alphainhibin is a tumour-suppressor gene with gonadal specifi city in mice. Nature 360: 313—319.[CrossRef][Medline]
[Order article via Infotrieve]
- Mitlak BH, Cohen FJ (1999). Selective estrogen receptor modulators: A look ahead. Drugs 57: 653—663.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Murphy ED, Beamer WG (1973). Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the Wx-Wu genotype. Cancer Res 33: 721—723.[Abstract/Free Full Text]
- Niswender GD, Chen CL, Midgley AR, Jr, Meites J., Ellis S. (1969). Radioimmunoassay for rat prolactin. Proc Soc Exp Biol Med 130: 793—797.[CrossRef][Medline]
[Order article via Infotrieve]
- Risma KA, Hirshfi eld AN, Nilson JH (1997). Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology 138: 3540—3547.[Abstract/Free Full Text]
- Schering Corporation (1997). Fareston® Package Insert. Kenilworth, NJ.
- Sato M., Rippy MK, Bryant HU (1996). Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10: 905—912.[Abstract]
- Scully KM, Gleiberman AS, Lindzey J., Lubahn DB, Korach KS, Rosenfeld MG (1997). Role of estrogen receptor-alpha in the anterior pituitary gland. Mol Endocrino l 11: 674 —681.[CrossRef]
- Tucker MJ, Adam HK, Patterson JS (1984). Tamoxifen. In: Safety Testing of New Drugs, Laurence DR, McLean AEM, Weatherall M (eds). Academic Press, London, pp 125—161.
- . Weiss NS, Hill DA ( 1996). Postmenopausa l estrogens and progestogen s and the incidence of gynecologic cancer. Maturitas 23: 235—239.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yang NN, Venugopala n M., Hardikar S., Glasebrook A. (1996). Identifi cation of an estrogen respons e element activated by metabolites of 17beta-estradiol and raloxifene. Science 273: 1222—1225.[Abstract]
Toxicologic Pathology, Vol. 29, No. 6,
719-726 (2001)
DOI: 10.1080/019262301753386031
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
